| RUNX1 could act as a tumor suppressor gene in breast cancer. | breast, |
| miR-675 was positively expressed with H19 and was a pivotal mediator in H19-induced gastric cancer cell growth promotion. Subsequently, the tumor suppressor Runt Domain Transcription Factor1 (RUNX1) was confirmed to be a direct target of miR-675. | gastric, |
| Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer | breast, |
| identification as tumor suppressor gene | None |
| both repressor and activator functions of Runx1 at multiple hematopoietic stages and lineages likely contribute to the tumor suppressor activity in MDS and AML. | None |
| RUNX1 in T-ALL: tumor suppressive or oncogenic? | None |
| Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. | leukemia, |
| Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. | leukemia, |
| Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal. | leukemia, |
| AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. | leukemia, |
| c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein. | leukemia, |
| Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. | lymphoma, |
| Oncogene AML-1 protein is detected frequently in acute myelogenous leukemia and it is a favorable prognostic factor in disease survival. | leukemia, |
| Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. | leukemia, |
| Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. | leukemia, |
| The TCR gene rearrangements in childhood B-lineage acute lymphoblastic leukemia was associated with expression of AML1 chimeric oncogene. | leukemia, |
| The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression. | leukemia, |
| Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. | leukemia, |
| Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. | leukemia, |
| Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. | leukemia, |